# Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

> **NCT06811233** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 140 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** DMSA
- **DRUG:** Ca-EDTA
- **DRUG:** Magnesium Sulfate
- **DRUG:** Multivitamin

## Key facts

- **NCT ID:** NCT06811233
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2029-08-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06811233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06811233, "Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06811233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*